

FASTNIB-FORTE TABLETS

Tofacitinib Citrate I.P. 11 mg

"Advanced JAK Inhibition for Severe Autoimmune & Inflammatory Disorders"

Marketed by: Human Orthocare

A Subsidiary of Human Biolife India Pvt. Ltd.

www.humanorthocare.com



Product Overview

Composition (per tablet):

Tofacitinib Citrate I.P. – 11 mg

Key Features:

- Equivalent to *Tofacitinib XR 11 mg (extended release)*
- Once-daily dosing for better compliance
- Potent *Janus Kinase (JAK) inhibitor* → targets multiple cytokine pathways
- Effective oral therapy for moderate to severe autoimmune diseases





**Human
Ortho Care**

A SUBSIDIARY OF HUMAN BIOLIFE INDIA PVT. LTD.

Mechanism of Action



JAK Inhibition

Selectively inhibits JAK1 & JAK3, partially JAK2



STAT Pathway Blockade

Blocks STAT pathway → reduces cytokine signalling (IL-2, IL-4, IL-6, IL-7, IL-15, IL-21, interferons)



Immune Suppression

Suppresses immune hyperactivation & chronic inflammation

Result: Reduces joint damage, inflammation & systemic autoimmune activity



Indications

Fastnib-Forte Tablets are recommended for:

Rheumatoid Arthritis

Moderate to severe cases requiring advanced therapy

Psoriatic Arthritis

Comprehensive treatment for joint and skin manifestations

Ankylosing Spondylitis

Effective control of spinal inflammation and mobility

Ulcerative Colitis

Moderate to severe inflammatory bowel disease

Other autoimmune disorders as per specialist guidance



Clinical Advantages

Key Benefits of Fastnib-Forte:



Once-Daily XR Dose

Better compliance versus 5 mg BID formulation. Extended release technology ensures consistent therapeutic levels throughout the day.



Enhanced Efficacy

Stronger efficacy in severe or resistant autoimmune cases. Rapid onset of action with faster reduction in pain, swelling & stiffness.



Convenient Alternative

Oral therapy alternative to biologics - no injections required. Significantly improves patient function & quality of life.

Comparison with Fastnib-5

Tofacitinib 5 mg BID versus 11 mg XR Once Daily

Parameter	Fastnib-Forte (11 mg XR OD)	Fastnib-5 (5 mg BID)
Dosing Frequency	✓ Once Daily	✗ Twice Daily
Compliance	✓ Better	⚠ Moderate
Efficacy in Severe RA/UC	✓ Stronger	⚠ Moderate
Monitoring Needs	✓ Same (CBC, LFT, Lipids)	✓ Same

Dosage & Administration

Standard Dosage

1

11 mg once daily (XR formulation)

Indicated for RA, PsA, AS & UC as per guidelines

Dose Adjustment

2

Adjust dose in hepatic/renal impairment according to clinical guidelines

⚠ Important Considerations:

- Avoid with strong immunosuppressants (biologics, cyclosporine)
- Regular monitoring: CBC, LFTs, lipid profile



Safety & Tolerability

Common Side Effects

- Headache
- Gastrointestinal upset
- Hypertension
- Increased cholesterol & liver enzyme levels

Serious but Rare Risks

- Opportunistic infections (TB, herpes zoster)
- Thrombosis & embolism (dose-related)
- Malignancy risk with long-term therapy

⊗ Contraindications

- Severe hepatic impairment
- Active serious infections
- Pregnancy & lactation



Why Prescribe Fastnib-Forte?

Doctor's Choice For:

- Superior Compliance**
Once-daily XR formulation significantly improves patient adherence compared to twice-daily dosing regimens
- Enhanced Efficacy**
Stronger efficacy in severe autoimmune conditions with rapid control of inflammation & joint damage
- Treatment Alternative**
Ideal for patients resistant or intolerant to conventional DMARDs or TNF inhibitors
- Trusted Quality**
Backed by the reliability and expertise of Human Orthocare



Contact Us

Step into care that moves you forward.

Use with clinical discretion, especially in high-risk orthopedic conditions.

HumAn Orthocare – A Subsidiary of Human Biolife India Pvt. Ltd.

For medical queries or collaboration:

 www.humanorthocare.com